The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to study the safety and feasibility of anti- Mesothelin
Chimeric Antigen Receptor T-Cell (MESO CAR-T cells) therapy for Refractory-Relapsed Ovarian
Cancer